SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
+14.15%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$80.3M
AUM Growth
+$80.3M
(-4.3%)
Cap. Flow
-$14.2M
Cap. Flow
% of AUM
-17.64%
Top 10 Holdings %
Top 10 Hldgs %
61.84%
Holding
47
New
13
Increased
9
Reduced
9
Closed
11
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$5.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$4.74M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$4.68M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$3.88M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$1.76M |
Top Sells
| 1 |
Zai Lab
ZLAB
|
$5.6M |
| 2 |
Legend Biotech
LEGN
|
$5.44M |
| 3 |
Pfizer
PFE
|
$4.97M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$4.81M |
| 5 |
UroGen Pharma
URGN
|
$4.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cogent Biosciences
COGT
$1.69B
| $6.91M | 8.19% | 962,951 +188,230 | +24% | +$1.35M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $6.52M | 7.73% | 68,982 -27,839 | -29% | -$2.63M |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $5.1M | 6.04% | +40,608 | New | +$5.1M |
|
4
Terns Pharmaceuticals
TERN
$609M
| $4.8M | 5.68% | 1,286,681 -70,472 | -5% | -$263K |
|
|
5
Ultragenyx Pharmaceutical
RARE
$2.89B
| $4.74M | 5.61% | +130,422 | New | +$4.74M |
|
|
6
Zai Lab
ZLAB
$3.68B
| $4.72M | 5.59% | 134,895 -160,052 | -54% | -$5.6M |
|
|
7
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4.68M | 5.54% | +44,107 | New | +$4.68M |
|
8
BridgeBio Pharma
BBIO
$9.89B
| $4.18M | 4.95% | 96,766 -87,156 | -47% | -$3.76M |
|
9
Travere Therapeutics
TVTX
$1.56B
| $4.09M | 4.84% | 276,474 +38,987 | +16% | +$577K |
|
|
10
Ionis Pharmaceuticals
IONS
$6.79B
| $3.88M | 4.6% | +98,267 | New | +$3.88M |
|
|
11
Oric Pharmaceuticals
ORIC
$994M
| $3.5M | 4.15% | 344,922 -474,272 | -58% | -$4.81M |
|
12
Soleno Therapeutics
SLNO
$3.6B
| $2.82M | 3.34% | 33,691 +14,359 | +74% | +$1.2M |
|
13
Savara
SVRA
$567M
| $2.54M | 3.01% | 1,115,379 +149,176 | +15% | +$340K |
|
14
89bio
ETNB
$1.34B
| $2.09M | 2.47% | 212,377 +103,221 | +95% | +$1.01M |
|
15
Cytokinetics
CYTK
$4.23B
| $2.02M | 2.39% | 61,103 -11,889 | -16% | -$393K |
|
|
BCAX
16
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $1.76M | 2.09% | +189,699 | New | +$1.76M |
|
17
Cabaletta Bio
CABA
$133M
| $1.61M | 1.91% | 1,060,764 +601,792 | +131% | +$915K |
|
|
TECX
18
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $1.57M | 1.86% | 79,058 +28,312 | +56% | +$563K |
|
19
Insmed
INSM
$28.8B
| $1.47M | 1.74% | +14,571 | New | +$1.47M |
|
20
United Therapeutics
UTHR
$13.8B
| $1.4M | 1.66% | +4,874 | New | +$1.4M |
|
21
Avidity Biosciences
RNA
$5.99B
| $1.34M | 1.58% | 47,037 +24,766 | +111% | +$703K |
|
|
22
UroGen Pharma
URGN
$900M
| $1.2M | 1.43% | 87,912 -335,720 | -79% | -$4.6M |
|
23
Protara Therapeutics
TARA
$120M
| $1.09M | 1.29% | 360,000 | – | – |
|
|
ZBIO
24
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $1.08M | 1.28% | 111,605 | – | – |
|
25
Liquidia Corp
LQDA
$2.38B
| $886K | 1.05% | +71,071 | New | +$886K |
|